Cargando…

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS mutations, recently questioned for its validity, and alternative mutation-based biomarkers were proposed. We set out to investigate whether an expression signature can also predict response by utilizi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Sheng, Chen, Dawei, Huang, Xuesong, Cai, Jie, Wery, Jean-Pierre, Li, Qi-Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226604/ https://www.ncbi.nlm.nih.gov/pubmed/27409671 http://dx.doi.org/10.18632/oncotarget.10499

Ejemplares similares

A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations
por: Chen, Dawei, et al.
Publicado: (2015)

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
por: Zheng, Peng, et al.
Publicado: (2018)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model
por: Jiang, Jiahua, et al.
Publicado: (2015)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC
por: Yuan, Yitao, et al.
Publicado: (2023)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts
por: Leskoske, Kristin L., et al.
Publicado: (2022)

Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
por: Rio-Vilariño, Anxo, et al.
Publicado: (2021)

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts
por: Reissig, Timm M., et al.
Publicado: (2023)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
por: Rivera, Maria, et al.
Publicado: (2020)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

No back seat for a progression event—K-RAS as a therapeutic target in CRC
por: Poulin, Emily J., et al.
Publicado: (2017)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models
por: Matsuo, Teppei, et al.
Publicado: (2011)

Pretargeting of internalizing trastuzumab and cetuximab with a (18)F-tetrazine tracer in xenograft models
por: Keinänen, Outi, et al.
Publicado: (2017)

CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b
por: Zhang, Qi, et al.
Publicado: (2023)

Not everything is as it seems
por: Biyani, Ghansham, et al.
Publicado: (2020)

CAM-Xenograft Model Provides Preclinical Evidence for the Applicability of [(68)Ga]Ga-Pentixafor in CRC Imaging
por: Benčurová, Katarína, et al.
Publicado: (2022)

Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression
por: Wei, Zhenzhen, et al.
Publicado: (2023)

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
por: Loboda, Andrey, et al.
Publicado: (2010)

Microbiome distinctions between the CRC carcinogenic pathways
por: DeDecker, Lauren, et al.
Publicado: (2021)

Eosinophilic gastrointestinal disorder: is it what it seems to be?
por: Zammit, Stefania Chetcuti, et al.
Publicado: (2018)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
por: Sommariva, Michele, et al.
Publicado: (2013)

Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer
por: Miyamoto, Ryoichi, et al.
Publicado: (2016)

Improving the overall survival prognosis prediction accuracy: A 9‐gene signature in CRC patients
por: Zheng, Wenbo, et al.
Publicado: (2021)

OIDC, it seems to be hip
por: Wezepoel, Tom
Publicado: (2023)

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer
por: Wei, Li, et al.
Publicado: (2020)

CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer
por: Nguyen, Minh Nam, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3i0egq1f07ju8rmdd633da5qrd